Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol

about

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol

Item

http://www.wikidata.org/entity/Q26775244

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Differential pharmacology and ...... in COPD - focus on olodaterol

@ast

Differential pharmacology and ...... in COPD - focus on olodaterol

@en

Differential pharmacology and ...... in COPD - focus on olodaterol

@nl

type

Item

label

Differential pharmacology and ...... in COPD - focus on olodaterol

@ast

Differential pharmacology and ...... in COPD - focus on olodaterol

@en

Differential pharmacology and ...... in COPD - focus on olodaterol

@nl

prefLabel

Differential pharmacology and ...... in COPD - focus on olodaterol

@ast

Differential pharmacology and ...... in COPD - focus on olodaterol

@en

Differential pharmacology and ...... in COPD - focus on olodaterol

@nl

P1476

Differential pharmacology and ...... in COPD - focus on olodaterol

@en

P2093

Josuel Ora

http://www.w3.org/2001/XMLSchema#string

Maria Gabriella Matera

http://www.w3.org/2001/XMLSchema#string

Mario Cazzola

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

β(2) -adrenoceptor agonists: current and future direction

Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.

Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy.

Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models.

The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.

P304

1805-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S73581

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26676161

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

chronic obstructive pulmonary disease

P932

4675639

http://www.w3.org/2001/XMLSchema#string